Marisa Wexler, MS,  senior science writer—

Since the introduction of Kalydeco (ivacaftor) in the U.K., marked changes in treatment patterns for cystic fibrosis (CF) patients using the medication have become noticeable over time, a study reported. Specifically, people treated with Kalydeco were less likely to continue with other treatments, such as inhaled antibiotics or…

Bacteria living in the gut are abnormally slow to develop functional abilities in infants with cystic fibrosis (CF), which may affect their nutrition, growth, and gastrointestinal health, a study reported. Therapies targeting the gut microbiome could be “promising avenues” to improving their overall health, its researchers suggested. The study,…

Epicore Biosystems has launched in the U.S. a wearable patch allowing it to collect and analyze sweat for biomarker research, the company announced. Called the Discovery Patch Sweat Collection System, it may be useful in monitoring changes in sweat chloride in people with cystic fibrosis (CF), among other applications.

Students living with cystic fibrosis (CF) and attending or starting college, either at the undergraduate or graduate level, are invited to apply for one of 30 “Sacks for CF” scholarships. The annual program is run by the Boomer Esiason Foundation, a nonprofit dedicated to helping people with CF. Every…

Cystic Fibrosis Canada has opened an initiative called Elevate, inviting people affected by cystic fibrosis (CF) to share their experiences, perspectives, and priorities with the nonprofit group.  “We have a history of asking for input from the community, but we felt…

A research ethics committee in Australia has given Krystal Biotech the go-ahead to start a Phase 1 clinical study of KB407, the company’s investigational inhaled gene therapy for cystic fibrosis (CF). Enrollment for the trial is expected to start soon, according to Krystal, following approval from the…

The publicly funded drug access programs in the Canadian provinces of Alberta and Saskatchewan are now covering the triple-combination therapy Trikafta for eligible patients with cystic fibrosis (CF). These provinces join Ontario as the first to confirm coverage of Trikafta in Canada. “It’s a relief to know that…

People with cystic fibrosis (CF) in Ontario, Canada, will now have access to the triple-combination therapy Trikafta through the province’s publicly funded drug program. “Our government has taken urgent action to ensure all cystic fibrosis patients will have more timely access to the effective and lifechanging treatments they need,”…

A two-day virtual event called BreatheCon will offer adults with cystic fibrosis (CF) an opportunity to connect and share their experiences through open and honest dialogue. Registration for the Sept. 24–25 event, which is hosted by the Cystic Fibrosis Foundation, is free online. “CF can be extremely…

Increasing the levels of the SFPQ protein helped to restore expression and function of the CFTR protein in cells with a F508del mutation in the CFTR gene, the most common cause of cystic fibrosis (CF). Work also showed that SFPQ levels were unusually low in these cells, suggesting this protein “may play…